Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 13/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30982343 | 1.00 | MAP2K4 (0.46) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL5635078 | 0.83 | GSK3B (0.42) | MAP2K4GPR84 | |
| SCHEMBL5637828 | 0.81 | PDPK1 (0.51) | — | |
| SCHEMBL7713988 | 0.81 | MAP2K4 (0.49) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL24253274 | 0.81 | MAP2K4 (0.43) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL5335207 | 0.78 | DYRK1A (0.42) | MAP2K4ITKHTR2A | |
| SCHEMBL5953156 | 0.77 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL320109 | 0.77 | KDM4E (0.46) | — | |
| SCHEMBL5677771 | 0.77 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL19570332 | 0.77 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388581-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12331052-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240415832-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-12-19 | — | — | US | disclosed |
| CN-118105390-A | Method for treating addiction | 细胞内治疗公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| CN-113905737-A | Method of treating neuropathic pain | 细胞内治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-113329742-A | Method for treating addiction | 细胞内治疗公司 | 2021-08-31 | — | — | CN | disclosed |
| US-10906906-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190345160-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3562484-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018126143-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1192165-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | MAP2K4 3392/4885MAPK1 3651/4885MAPK6 3678/4885 |
| US-20190345160-A1 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | MAP2K4 1692/4885MAPK1 1469/4885MAPK6 2693/4885 |
| US-20250388581-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | MAP2K4 634/4885MAPK1 1106/4885MAPK6 1305/4885 |
| US-12331052-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | MAP2K4 1885/4885MAPK1 1515/4885MAPK6 2455/4885 |
| US-20240415832-A1 | NOVEL METHODS | OPRK1, OPRD1, OPRM1 | MAP2K4 3257/4885MAPK1 4221/4885MAPK6 4639/4885 |
| US-10906906-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | MAP2K4 1790/4885MAPK1 1020/4885MAPK6 1973/4885 |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | OPRK1, OPRM1, OPRD1 | MAP2K4 2568/4885MAPK1 3445/4885MAPK6 3692/4885 |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | MAP2K4 3392/4885MAPK1 3651/4885MAPK6 3678/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | MAP2K4 1692/4885MAPK1 1462/4885MAPK6 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.